Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: a real-world study from Saudi Arabia
European Archives of Oto-Rhino-Laryngology · 2025-11 · 282 (11) · 5675-5682
DOI: 10.1007/s00405-025-09677-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 18.09.2025. Verfasst von Abdullah S Alghamdi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rhinology, Endoscopic Sinus & Skull Base, King Abdullah Medical City, Makkah, Saudi Arabia. asdnjm@hotmail.com. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Rhinitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP), often Linked to asthma, significantly affects quality of life. While dupilumab 300 mg every two weeks (Q2W) is effective, it is costly. This real-world Saudi study evaluated whether extending dosing to every four weeks (Q4W) maintains effectiveness in patients with or without asthma. METHODS: In this retrospective single-cohort study, 42 adults with CRSwNP who completed at least one year of stable Q2W dupilumab therapy were transitioned to Q4W and followed for one additional year. Clinical, biomarker, and imaging outcomes were analyzed. RESULTS: Clinical outcomes between Q2W and Q4W were largely comparable. Eight CRSwNP patients had comorbid asthma (19%). Median nasal polyp scores remained stable, and symptom scores for nasal congestion, discharge, smell loss, and fatigue showed no significant changes. Sino-Nasal Outcome Test (SNOT)-22 and Lund-Mackay scores trended lower in the Q4W group compared to Q2W group but were not statistically significant. Blood eosinophils were modestly reduced, while asthma control remained stable, with high asthma control test scores. Total IgE levels (IU/mL) were significantly lower in the Q4W group (32.5 [10.1-76.4] vs. 52.7 [19.8-215], p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rhinology, Endoscopic Sinus & Skull Base, King Abdullah Medical City, Makkah, Saudi Arabia. asdnjm@hotmail.com.
- Department of Rhinology, Endoscopic Sinus & Skull Base, King Abdullah Medical City, Makkah, Saudi Arabia.
- Department of Allergy and Immunology, Department of Specialized Internal Medicine, King Abdullah Medical City, Makkah, Saudi Arabia.
- Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Zitieren
APA
Alghamdi, A. S., Saati, F. A., Alkhammash, S., Bulkhi, A. A., Muathen, S. H., & Abu Suliman, O. A. (2025). Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: a real-world study from Saudi Arabia. European Archives of Oto-Rhino-Laryngology, 282(11), 5675-5682. https://doi.org/10.1007/s00405-025-09677-2
Vancouver
Alghamdi AS, Saati FA, Alkhammash S, Bulkhi AA, Muathen SH, Abu Suliman OA. Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: a real-world study from Saudi Arabia. European Archives of Oto-Rhino-Laryngology. 2025;282(11):5675-5682. doi:10.1007/s00405-025-09677-2
BibTeX
@article{Alghamdi2025,
author = {Alghamdi, Abdullah S and Saati, Faisal A and Alkhammash, Salma and Bulkhi, Adeeb A and Muathen, Sumaiya H and Abu Suliman, Omar A},
title = {Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: a real-world study from Saudi Arabia},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2025},
volume = {282},
number = {11},
pages = {5675--5682},
doi = {10.1007/s00405-025-09677-2}
}
EUVIMED